NASDAQ:ALKS

Alkermes Stock Forecast, Price & News

$25.77
+1.63 (+6.75 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.14
$25.91
50-Day Range
$21.59
$25.77
52-Week Range
$15.35
$25.91
Volume1.62 million shs
Average Volume1.65 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.98
30 days | 90 days | 365 days | Advanced Chart
Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.


Alkermes logo

About Alkermes

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

1062nd out of 2,210 stocks

Pharmaceutical Preparations Industry

508th out of 867 stocks

Analyst Opinion: 1.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes
or view top-rated stocks.

What stocks does MarketBeat like better than Alkermes?

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alkermes wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for Alkermes
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Tuesday, April, 27th. The company reported $0.11 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.13. The firm had revenue of $251.43 million for the quarter, compared to analyst estimates of $233.78 million. Alkermes had a negative trailing twelve-month return on equity of 0.15% and a negative net margin of 9.06%. The business's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.01 earnings per share.
View Alkermes' earnings history
.

How has Alkermes' stock been impacted by Coronavirus (COVID-19)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALKS shares have increased by 58.6% and is now trading at $25.77.
View which stocks have been most impacted by COVID-19
.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2021 earnings guidance on Wednesday, July, 28th. The company provided EPS guidance of $0.520-$0.700 for the period, compared to the Thomson Reuters consensus estimate of $0.510. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for ALKS?

6 equities research analysts have issued 12-month target prices for Alkermes' stock. Their forecasts range from $15.00 to $29.00. On average, they expect Alkermes' stock price to reach $22.20 in the next twelve months. This suggests that the stock has a possible downside of 13.9%.
View analysts' price targets for Alkermes
or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $25.77.

How much money does Alkermes make?

Alkermes has a market capitalization of $4.13 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,245 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

Where are Alkermes' headquarters?

Alkermes is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.